SAN DIEGO, Feb. 8, 2022 /PRNewswire/ -- Evofem
Biosciences, Inc., (NASDAQ: EVFM) will present at the Aegis
Virtual Conference as follows:
|
Date:
|
Wednesday, February
23, 2022
|
|
Time:
|
4:30 p.m. ET (1:30
p.m. PT)
|
|
Access
Webcast:
|
https://evofem.investorroom.com/Aegis2022
or
https://us02web.zoom.us/j/86168915443
|
|
Add to
Calendar:
|
iCalendar (.ics)
file
|
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is developing and commercializing innovative
products to address unmet needs in women's sexual and reproductive
health, including hormone-free, woman-controlled contraception and
protection from certain sexually transmitted infections (chlamydia
and gonorrhea). The Company's first FDA-approved
product, Phexxi® (lactic acid, citric acid and potassium
bitartrate), is a hormone-free, on-demand prescription
contraceptive vaginal gel. It comes in a box of 12 pre-filled
applicators and is applied 0-60 minutes before each act of sex.
Learn more at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem
Biosciences, Inc.
Investor Relations Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
View original content to download
multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-aegis-virtual-conference-on-wednesday-february-23-2022-301477311.html
SOURCE Evofem Biosciences, Inc.